HeloisaPradoSoaresMD

Oncology • Salt Lake City, UT

Endocrine Cancer, Gastrointestinal Cancer, Hematologic Oncology

Associate Professor

Join to view full profile

Dr. Soares is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Soares' full profile

Already have an account?

Office
2000 Circle of Hope Dr
Salt Lake City, UT 84112
Phone+1 801-646-4016

Fax+1 801-585-0124

Education & Training

UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 2010 - 2013
Mount Sinai Medical Center of FloridaResidency, Internal Medicine, 2007 - 2010
OtherClass of 2002

Certifications & Licensure

UT State Medical License 2019 - 2026
ID State Medical License 2021 - 2025
MT State Medical License 2021 - 2025
WY State Medical License 2021 - 2025
NV State Medical License 2021 - 2023
CA State Medical License 2010 - 2021
FL State Medical License 2015 - 2021
NM State Medical License 2017 - 2021
Join now to see all

Awards, Honors, & Recognition

Society of Huntsman Translational Scholars Hunstman Cancer Institute at University of Utah, 2024
Hematology and Medical Oncology Fellowship Faculty Teaching Award Huntsman Cancer Institute at University of Utah, 2021
“40 Under 40 in Cancer” award The Lynx Group™ and McGivney Global Advisors, 2018
Intern of the Year Mount Sinai Medical Center of Florida, 2008
Join now to see all

Clinical Trials

Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy Start of enrollment: 2022 Mar 24
Active, not recruiting
Phase 3
Roles: Contact
Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE Start of enrollment: 2021 Dec 21
Recruiting
Phase 3
Roles: Contact, Principal Investigator
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors Start of enrollment: 2022 May 05
Recruiting
Phase 2
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease Start of enrollment: 2022 Mar 10
Recruiting
Phase 2, Phase 3
Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine Cancer Start of enrollment: 2021 Mar 17
Recruiting
Phase 2
Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used With Targeted Radiation-based Treatment (Lutetium Lu 177 Dotatate), Compared to Lutetium Lu 177 Dotatate Alone for Metastatic Neuroendocrine Tumors Start of enrollment: 2023 Aug 30
Recruiting
Phase 2
Iadademstat in Combination With Paclitaxel in Relapsed/Refractory SCLC and Extrapulmonary High Grade NET Start of enrollment: 2022 Dec 21
Recruiting
Phase 2
Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors Start of enrollment: 2022 Mar 16
Recruiting
Phase 2
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer, the COMMIT Study Start of enrollment: 2018 Jan 19
Recruiting
Phase 3
Comparing Retreatment of 177Lu-DOTATATE PRRT Versus Everolimus in Patients With Metastatic Unresectable Midgut Neuroendocrine Tumors, NET RETREAT Trial Start of enrollment: 2024 Jan 12
Recruiting
Phase 2
Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors Start of enrollment: 2023 Feb 03
Recruiting
Phase 2
Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung Start of enrollment: 2022 Jun 28
Recruiting
Phase 2, Phase 3
Join now to see all

Publications & Presentations

PubMed

KRAS Mutation Status and Treatment Outcomes in Patients With Metastatic Pancreatic Adenocarcinoma.
Carter Norton, Matthew Steven Shaw, Zachary Rubnitz, Jarrod Smith, Heloisa P Soares
JAMA Network Open. 2025-01-02
BilT03: Phase 1b/2 multicenter trial of nivolumab with 5-fluorouracil and liposomal irinotecan for previously treated advanced biliary tract cancer.
Vaibhav Sahai, Kent A Griffith, Bruce S Lin, Heloisa P Soares, Sreenivasa R Chandana
Med. 2024-12-18
Characterization of Somatostatin Receptor 2 Gene Expression and Immune Landscape in Sinonasal Malignancies.
Elisabetta Xue, Dara Bracken-Clarke, Harris Krause, Tolulope Adeyelu, Mark G Evans
Cancers. 2024-11-24

Press Mentions

KRAS Mutations Linked to Varied Treatment Outcomes in Metastatic Pancreatic CancerJanuary 9th, 2025
The Society of Huntsman Translational Scholars Welcomes Two More MembersAugust 12th, 2024
Strategy 2025 Update: Directed Steps for University of Utah Health and Our CommunityMarch 1st, 2023
Join now to see all

Professional Memberships

American Society of Clinical Oncology - ASCO
Member

Other Languages

Spanish, Portuguese

External Links

Linkedinhttps://www.linkedin.com/in/heloisa-soares-gi-oncology
University of Utahhttps://healthcare.utah.edu/fad/mddetail.php?physicianID=u6026577&name=heloisa-p-soares